Abstract:Background: Gastrointestinal stromal tumors (GISTs) are the prevailing sarcomas of the gastrointestinal tract. Tyrosine kinase inhibitors (TKIs) therapy, exemplified by Imatinib mesylate (IM), constitutes the established adjuvant therapy for GISTs. Nevertheless, post-treatment resistance poses a challenge that all patients must confront. The presence of tumor heterogeneity and secondary mutation mechanisms fail to account for some instances of acquired drug resistance. Certain investigations suggest a strong association between tumor drug resistance and mesenchymal stromal cells (MSC) in the tumor microenvironment, but the underlying mechanism remains obscure. Scarce research has explored the connection between GIST drug resistance and the tumor microenvironment, as well as the corresponding mechanism. Methods: Immunofluorescence and fluorescence-activated cell sorting (FACS) methodologies were employed to detect the presence of MSC in GIST samples. The investigation encompassed the examination of MSC migration towards tumor tissue and the impact of MSC on the survival of GIST cells under IM treatment. Through ELISA, western blotting, and flow cytometry analyses, it was confirmed that Transforming Growth Factor Beta 2 (TGF-β2) triggers the activation of the PI3K-AKT pathway by MSC, thereby facilitating drug resistance in GIST. Results: Our findings revealed a positive correlation between a high proportion of MSC and both GIST resistance and a poor prognosis. In vitro studies demonstrated the ability of MSC to migrate towards GIST. Additionally, MSC were observed to secrete TGF-β2, consequently activating the PI3K-AKT pathway and augmenting GIST resistance. Conclusions: Our investigation has revealed that MSC within GISTs possess the capacity to augment drug resistance, thereby highlighting their novel mechanism and offering a promising target for intervention in GIST therapy.

Advances in immunotherapy of M2 macrophages and gastrointestinal stromal tumor

An update on molecular genetics and drug resistance of gastrointestinal stromal tumors

Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers

Molecular characteristics and immune microenvironment of gastrointestinal stromal tumours: targets for therapeutic strategies

Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges

Gastrointestinal stromal tumors regulate macrophage M2 polarization through the MIF/CXCR4 axis to immune escape

Potential therapeutic targets in myeloid cell therapy for overcoming chemoresistance and immune suppression in gastrointestinal tumors

Advances in Drug Therapy for Gastrointestinal Stromal Tumour

Research progress on the mechanism of imatinib resistance in gastrointestinal stromal tumor: from classical perspective to immune microenvironment perspective

New Developments in Gastrointestinal Stromal Tumor

Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update

Some Hot Spots in the Treatment of Gastrointestinal Stromal Tumor

Molecular targeted therapy for the treatment of gastrointestinal stromal tumor

[Strategies in Diagnosis and Management for Advanced or Metastatic Gastrointestinal Stromal Tumor].

Imatinib in Patients with Advanced Gastrointestinal Stromal Tumours (Gists)

The management of metastatic GIST: current standard and investigational therapeutics

Molecular Classification and Targeted Therapy of Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumor and Its Adjuvant Therapy

Mesenchymal stromal cells promote the drug resistance of gastrointestinal stromal tumors by activating the PI3K-AKT pathway via TGF-β2

Clinical Experience in Diagnosis and Treatment of Malignant Gastrointestinal Stromal Tumors

Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours